ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,750.63
0.21%
Dow Jones
44,546.08
-0.37%
Gold vs US Dollar
2,902.595
0.69%
Brent Oil
74.58
0.46%
Bitcoin
96,401.76
0.28%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) News

Moleculin Biotech (MBRX)

Moleculin Biotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MBRX
DateTimeSourceHeadlineSymbolCompany
13/02/202521:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/02/202518:05PR Newswire (US)Moleculin Announces Exercise of Warrants for $5.8 Million Gross ProceedsNASDAQ:MBRXMoleculin Biotech Inc
13/02/202514:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/02/202514:25PR Newswire (US)Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
11/02/202514:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
11/02/202513:40PR Newswire (US)Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal TrialNASDAQ:MBRXMoleculin Biotech Inc
11/02/202513:31Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
10/02/202513:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
10/02/202513:32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
29/01/202514:18Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
27/01/202517:08Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
27/01/202514:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
27/01/202513:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
27/01/202513:30PR Newswire (US)Moleculin Participates in Virtual Investor "What This Means" SegmentNASDAQ:MBRXMoleculin Biotech Inc
08/01/202513:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
08/01/202513:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
08/01/202513:30PR Newswire (US)Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026NASDAQ:MBRXMoleculin Biotech Inc
18/12/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/12/202422:02Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBRXMoleculin Biotech Inc
11/12/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
11/12/202413:00PR Newswire (US)Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML ModelNASDAQ:MBRXMoleculin Biotech Inc
10/12/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBRXMoleculin Biotech Inc
03/12/202422:20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MBRXMoleculin Biotech Inc
18/11/202413:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
18/11/202413:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
18/11/202413:15PR Newswire (US)New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNASDAQ:MBRXMoleculin Biotech Inc
14/11/202413:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
14/11/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
14/11/202413:15PR Newswire (US)Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025NASDAQ:MBRXMoleculin Biotech Inc
12/11/202413:00PR Newswire (US)Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:MBRX

Your Recent History

LSE
0JQI
Kennedy-wilson
BIT
1MO
Altria
TG
GLBD
Invesco Global Corporate...
ASX
AHN
Athena Resources
BIT
HMLA
HSBC MSCI EM Latin Ameri...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads